Howard Sklamberg, drugs compliance director at US FDA, takes on global role at agency
This article was originally published in SRA
Howard Sklamberg, the director of the Office of Compliance at the US Food and Drug Administration’s drugs center CDER, is to become the agency’s deputy commissioner for global regulatory operations and policy, effective 13 January1.
You may also be interested in...
EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's COVID-19 vaccine.
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.
The UK Thalassaemia Society says that HTA body NICE fails to properly incorporate patient experiences into its decision making and that its patient engagement processes need reform. The marketing of Zynteglo, the gene therapy from bluebird bio for which the group is advocating, has just been temporarily suspended.